CytoDyn (OTCMKTS:CYDY – Get Free Report) released its earnings results on Friday. The biotechnology company reported ($0.02) EPS for the quarter, reports.
CytoDyn Price Performance
CytoDyn stock opened at $0.27 on Friday. The firm has a 50 day simple moving average of $0.29 and a 200-day simple moving average of $0.29. The stock has a market cap of $341.74 million, a price-to-earnings ratio of -26.90 and a beta of 1.12. CytoDyn has a 1-year low of $0.13 and a 1-year high of $0.49.
About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
See Also
- Five stocks we like better than CytoDyn
- Why Trump and Musk suddenly care about Fort Knox
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A Message From An Ex-CIA Officer About Trump
- Buy AES Immediately
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
